

# Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries: a systematic review and meta-analysis

Jean B. Nachega<sup>a,b,c,d</sup>, Olalekan A. Uthman<sup>e,f</sup>, Jean Anderson<sup>g</sup>, Karl Peltzer<sup>h,i</sup>, Sarah Wampold<sup>a</sup>, Mark F. Cotton<sup>d,j</sup>, Edward J. Mills<sup>k</sup>, Yuh-Shan Ho<sup>l</sup>, Jeffrey S.A. Stringer<sup>m,n</sup>, James A. McIntyre<sup>o,p</sup> and Lynne M. Mofenson<sup>q</sup>

**Objective:** To estimate antiretroviral therapy (ART) adherence rates during pregnancy and postpartum in high-income, middle-income, and low-income countries.

**Design:** Systematic review and meta-analysis.

**Methods:** MEDLINE, EMBASE, SCI Web of Science, NLM Gateway, and Google scholar databases were searched. We included all studies reporting adherence rates as a primary or secondary outcome among HIV-infected pregnant women. Two independent reviewers extracted data on adherence and study characteristics. A random-effects model was used to pool adherence rates; sensitivity, heterogeneity, and publication bias were assessed.

**Results:** Of 72 eligible articles, 51 studies involving 20 153 HIV-infected pregnant women were included. Most studies were from United States ( $n = 14$ , 27%) followed by Kenya ( $n = 6$ , 12%), South Africa ( $n = 5$ , 10%), and Zambia ( $n = 5$ , 10%). The threshold defining good adherence to ART varied across studies (>80, >90, >95, 100%). A pooled analysis of all studies indicated a pooled estimate of 73.5% [95% confidence interval (CI) 69.3–77.5%] of pregnant women who had adequate (>80%) ART adherence. The pooled proportion of women with adequate adherence levels was higher during the antepartum (75.7%, 95% CI 71.5–79.7%) than during postpartum (53.0%, 95% CI 32.8–72.7%;  $P = 0.005$ ). Selected reported barriers for nonadherence included physical, economic and emotional stresses, depression (especially postdelivery), alcohol or drug use, and ART dosing frequency or pill burden.

**Conclusion:** Our findings indicate that only 73.5% of pregnant women achieved optimal ART adherence. Reaching adequate ART adherence levels was a challenge in pregnancy, but especially during the postpartum period. Further research to

---

<sup>a</sup>Department of International Health, <sup>b</sup>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA, <sup>c</sup>Department of Medicine, <sup>d</sup>Centre for Infectious Diseases, <sup>e</sup>Center for Evidence-based Healthcare, Faculty of Health Sciences, Stellenbosch University, Cape Town, South Africa, <sup>f</sup>Department of Primary Care Sciences, Keele University, Staffordshire, UK, <sup>g</sup>Department of Gynecology and Obstetrics, Johns Hopkins Hospital, Baltimore, Maryland, USA, <sup>h</sup>Human Sciences Research Council, Pretoria, <sup>i</sup>University of the Free State, Bloemfontein, <sup>j</sup>Department of Pediatrics and Child Health, Tygerberg's Children Hospital, Faculty of Health Sciences, Stellenbosch University, Cape Town, South Africa, <sup>k</sup>Faculty of Health Sciences, University of Ottawa, Ottawa, Ontario, Canada, <sup>l</sup>Trend Research Centre, Asia University, Taichung, Taiwan, <sup>m</sup>Centre for Infectious Disease Research, Lusaka, Zambia, <sup>n</sup>University of Alabama at Birmingham, Birmingham, Alabama, USA, <sup>o</sup>Anova Health Institute, Johannesburg, <sup>p</sup>School of Public Health & Family Medicine, University of Cape Town, Cape Town, South Africa, and <sup>q</sup>Pediatric, Adolescent and Maternal AIDS Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA.

Correspondence to Jean B. Nachega, MD, PhD, Department of International Health, Global Disease Epidemiology and Control Program, Johns Hopkins University Bloomberg School of Public Health, 615N. Wolfe Street, Suite W5031, Baltimore, MD 21205, USA.

Tel: +1 410 955 2378; fax: +1 410 502 6733; e-mail: jnachega@jhsph.edu  
Received: 13 July 2012; revised: 6 August 2012; accepted: 14 August 2012.

DOI:10.1097/QAD.0b013e328359590f

investigate specific barriers and interventions to address them is urgently needed globally.

© 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins

*AIDS* 2012, **26**:2039–2052

**Keywords:** adherence, antiretroviral therapy, HIV infection, prevention of mother-to-child HIV transmission, pregnancy

## Introduction

Globally, an estimated 1.4 million HIV-infected women give birth each year, 91% of whom reside in sub-Saharan Africa [1]. Antiretroviral therapy (ART) use during and after pregnancy is critical both for preserving maternal health and for prevention of mother-to-child transmission (PMTCT) of HIV. In high-income countries, MTCT rates as low as 1–2% have been achieved with combination ART (cART) drug regimens during pregnancy, as well as use of elective cesarean delivery in some circumstances and avoidance of breastfeeding [2]. In low-income and middle-income countries where breastfeeding is common and access to PMTCT services can be problematic, MTCT rates can be as high as 25–48% [3,4].

The 2010 WHO guidelines for ART drug use for treatment of pregnant women and preventing HIV infection in infants in low-resource settings have expanded recommendations for ART in pregnant women. These guidelines also recommended more complex cART regimens for PMTCT and the continuation of ART prophylaxis for either mother or infant throughout the breastfeeding regardless of whether the woman requires immediate ART for her own health [5]. In low-income countries, there has been a rapid scale-up of both ART coverage among treatment-eligible pregnant women, and total PMTCT coverage (prophylaxis and therapy). In such settings, an estimated 34% of treatment-eligible pregnant women received cART and an estimated 48% of HIV-infected pregnant women received the most effective ART regimens for PMTCT [excluding single-dose nevirapine (sdNVP)] in 2010, up from 15% global PMTCT coverage in 2005; in sub-Saharan Africa, coverage was 54% [1,6]. Given the rapid ART scale-up and availability of more effective PMTCT ART regimens, WHO has set a goal of virtual elimination of MTCT by 2015 [7].

Ensuring adherence to prescribed ART continues to be a major public health concern in both high-income and low-income countries. Virologic and clinical success depend crucially on good adherence, and with poor adherence, the virus may quickly develop therapy-limiting drug resistance [8]. Studies prior to 2005 using older cART regimens suggested that sustained virological suppression is achieved only if at least 95% of prescribed

doses are taken [9]. More recent studies of ritonavir-boosted protease inhibitors or nonnucleoside reverse transcriptase inhibitor (NNRTI; e.g. efavirenz)-based regimens suggest that virological suppression may be achieved at more moderate levels (70–80%) of ART adherence because the high potency and longer half-lives of these newer ART regimens make them more forgiving of occasional missed ART doses [10–12]. Nevertheless, higher ART adherence is associated with better virological outcomes in a linear dose-response fashion; thus, maximum adherence should be encouraged in each patient [10–12]. Adherence is particularly important among pregnant and lactating women. In addition to nonadherence increasing the risk of virologic failure, maternal HIV disease progression, and potential development of drug resistant virus, there may be increased risk of MTCT. For treatment-eligible mothers, the ART regimen is continued during the postpartum period, and for those who are not eligible for treatment, continued use of triple antiretroviral regimens for the duration of breastfeeding may be used to prevent postnatal HIV transmission. Thus, continued adherence to cART in the postpartum period is also critical for both maternal health and PMTCT.

A recent multinational randomized trial, HPTN 052 [13], found that initiation of treatment of HIV-infected individuals with CD4 cell counts between 350 and 550 cells/ $\mu$ l significantly reduced transmission to their uninfected sexual partners compared to those who delayed treatment. Given high rates of HIV serodiscordance [14,15] among married or cohabiting couples affected by HIV in many settings, there is increasing impetus to start effective ART for HIV-infected pregnant women, even if they do not meet current indications to start ART, further emphasizing the importance of good adherence in this population. Indeed, pregnant women (who are identifiable, seek care, and are clearly sexually active) would be a prime target for earlier treatment, with synergy for PMTCT.

Data on ART adherence during pregnancy are limited, and no systematic review of ART adherence in pregnancy has been published. These data are critical especially now that there is a global movement toward use of triple ART prophylaxis during pregnancy and breastfeeding for PMTCT. We conducted a meta-analysis to estimate the proportion of women with adequate ART adherence

levels during pregnancy and postpartum in low-income, middle-income, and high-income countries.

## Methods

### Protocol and registration

The study background, rationale, and methods were specified in advance and documented in a study protocol (Appendix 1, <http://links.lww.com/QAD/A254>). The study protocol was submitted and accepted to PROSPERO register (CRD42012002246).

### Eligibility criteria

Type of studies: all studies [cross-sectional studies, cohort studies, randomized controlled trials (RCTs)] that reported ART adherence rates as a primary or secondary outcome. No language, publication date, or publication status restrictions were imposed. Types of participants: HIV-infected pregnant women on ART during antenatal care or postnatal period or both. Types of interventions: any type of ART. Types of outcome measures: adherence rates regardless of measures (such as self-reported, pill count, etc.).

### Information sources and search strategy

Two of the authors (Y.-S.H., O.A.U.) conducted searches on the following electronic databases (from inception to November 2011): PubMed, EMBASE, SCI Web of Science, NLM Gateway, and Google scholar. We used the following keywords: HIV or AIDS, pregnant\*, 'mother to child transmission', 'adherence', 'compliance', 'antiretroviral therapy' (see Appendix 1 for the full PubMed search strategy, <http://links.lww.com/QAD/A254>). We searched abstract of relevant conference proceedings from 2006 onward (the most recent ones that may not have been indexed in NLM Gateway meeting abstracts). In addition, the bibliographies of relevant review articles and selected articles were examined for pertinent studies.

### Study selection

Two authors (J.B.N. and O.A.U.) evaluated the eligibility of studies obtained from the literature search and worked independently to scan all abstracts and obtain full text of articles. In cases of discrepancy, agreement was reached by consensus.

### Data abstraction

J.B.N. and O.A.U. independently extracted and compared the data. For each study that met the selection criteria, details were extracted on study design, study population characteristics, and adherence measures.

### Data analysis

For the meta-analysis, we first stabilized the raw ART adherence proportions from each study using the Freeman–Tukey variant of the arcsine square root

transformed proportion [16] suitable for pooling. We used a DerSimonian–Laird random-effects model [17] due to anticipated variations in study population, healthcare delivery systems, and epidemic course. To evaluate the stability of the results, we applied several sensitivity analyses, including fixed-effects analysis and used a one-study removed approach [18]. The purpose of this analysis was to evaluate the influence of individual studies, by estimating pooled estimate in the absence of each study. We assessed heterogeneity among trials by inspecting the forest plots and using the  $\chi^2$  test for heterogeneity with a 10% level of statistical significance, and using the  $I^2$  statistic wherein we interpret a value of 50% as representing moderate heterogeneity [19,20]. We assessed the possibility of publication bias by evaluating a funnel plot for asymmetry. Because graphical evaluation can be subjective, we also conducted a Begg's adjusted rank correlation test [21] and Egger's regression asymmetry test [22] as formal statistical tests for publication bias.

The effect of study-level variables on the overall adherence rates was explored using subgroup and meta-regression analyses: stage of pregnancy (antepartum vs. postpartum), publication type (conference abstract vs. journal article), study design [observational vs. PMTCT interventional studies (e.g., adherence data collected as part of a clinical trial evaluating efficacy of PMTCT regimens, not ART adherence interventions)], study location (low-income and middle-income vs. high-income countries), type of ART regimen [zidovudine (ZDV), sdNVP, and combined ART (cART)], adherence threshold (>80, >90, >95, and 100%), and measure of adherence (pharmacy refills and claims-based, pill counts, self-reported and blood drug concentration). In addition, we conducted another subgroup analysis based on countries income group, after excluding studies that administered sdNVP and limited to studies that used 80% or more as threshold for good ART adherence levels, to evaluate whether there are differential proportion of women who achieved adequate adherence levels based on country-income group in studies that administered complex regimens as opposed to studies of sdNVP and studies that used high threshold of adherence levels.

Univariable and multivariable random-effects logistic regression analyses were conducted to investigate the impact of study characteristics on the pooled adherence proportions. Univariable random-effects logistic regression analyses were used to investigate the bivariate relationship between each study-level factor (listed above) and adherence estimates. Multivariable random-effects logistic regression analyses were carried out to determine which study-level factors were independently associated with adherence estimates. Meta-analysis results were reported as combined adherence proportions with 95% confidence intervals (CIs), whereas meta-regression results are reported as odds ratio with 95% CIs. Pearson correlation coefficient was used to examine the

association between adherence rates and MTCT of HIV. The Pearson correlation analyses were stratified by type of ART and type of study design. All *P* values are exact and *P* value less than 0.05 was considered significant. Analyses were conducted using Stata version 12 for Windows (Stata Corp, College Station, Texas, USA). This systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines (<http://www.prisma-statement.org>) [23,24]. PRISMA checklist is provided in the Appendix 2, <http://links.lww.com/QAD/A254>.

## Results

### Search results and study characteristics

Figure 1 shows the study selection flow diagram. The literature search yielded 560 articles. After review, 72 articles were selected for critical reading. Twenty-one studies did not meet the inclusion criteria and were excluded (see Appendix 3 for list of excluded studies, <http://links.lww.com/QAD/A254>). The other 51 studies [25–74] involving 20 153 HIV-infected pregnant women were included; 48 studies reporting 71 adherence estimates were included in the meta-analysis. The remaining three studies [56,64,75] reported ART adherence as mean or median adherence and could not be included in the meta-analysis. Kappa agreement was 0.96 between J.B.N. and O.U.A. for inclusion of studies in this meta-analysis.




Fig. 1. Study selection flow diagram.

Table 1 presents the characteristics of the included studies. The studies were carried out between 1986 and 2011 and reported between 1998 and 2011. Most were reported as journal articles ( $n=46$ , 90%); five were presented as conference abstracts (10%). The preponderance of the studies ( $n=38$ , 74%) was observational and 13 (26%) were RCTs evaluating PMTCT regimens. Most were carried out in the United States ( $n=14$ , 27%) followed by Kenya ( $n=6$ , 12%), South Africa ( $n=5$ , 10%), and Zambia ( $n=5$ , 10%). Most studies included pregnant women on triple regimen ART ( $n=23$ , 45%). Fifteen (29%) and 12 (24%) studies report adherence rates among HIV-infected pregnant women on ZDV and sdNVP, respectively. One study compared adherence between ZDV and triple regimen ART. Most (11 out of 12) of the sdNVP studies reported adherence among pregnant women who ingested the sdNVP at onset of labor at home. Only one study [61] reported adherence in both pregnant women who ingested sdNVP at home and those who ingested sdNVP during labor at least 2 h before delivery. The threshold used to define ART adherence varied across studies (>80, >90, >95, and 100%). Most studies measured adherence using self-reported questionnaires ( $n=26$ , 51%), followed by pill counting ( $n=9$ , 18%), and pharmacy refills or claims-based ( $n=5$ , 10%). Five studies (9%) used blood drug concentrations (cord blood [43,44,50,74] and red blood cells [36]) to measure ART adherence; one study used electronic Medication Events Monitoring System (MEMS caps) [64]. Most of the studies reported adherence during antepartum period ( $n=39$ , 76%), four (8%) reported adherence during postpartum period, and eight (16%) reported both antepartum and postpartum adherence rates.

### Overall adherence to antiretroviral therapy during and after pregnancy

Proportion of women who achieved adequate adherence levels and 95% CIs from individual studies with a pooled estimate are shown in Fig. 2. The pooled ART adherence proportions for all studies yielded an estimate of 73.5% (95% CI 69.3–77.5%) of patients with adequate ART adherence (>80%). The  $I^2$  statistics was 97.7%, indicating statistically significant heterogeneity among the studies. We found no significant publication bias (Egger's test,  $P=0.467$  and Begg's test,  $P=0.996$ ). The results of leave-one-study-out sensitivity analyses showed that no study had undue influence on pooled adherence estimate. Adherence estimates of the three studies not included in the meta-analysis were as follows: Chung *et al.* [56] reported that ART adherence was 96% by pill count; using MEMS caps, Ickovics *et al.* [64] reported that the mean adherence to antepartum ZDV was extremely low (50.0%), with a statistically significant decline in mean postpartum adherence after 3 weeks (34.1%;  $P=0.04$ ); Leisegang *et al.* [75] estimated median overall pharmacy claims-based ART adherence of women who were pregnant when starting ART at 54.0%.

Table 1. Overall characteristics of included studies.

Study	Publication year	Type of publication	Study year	Study design	Country	Income group	ARTs	Threshold	Adherence measure	Sample	Stage
Turner et al. [38]	1998	Abstract	NR	Obs.	USA	High	cART	80	Pharmacy-based	323	AN
Dabis et al. [25]	1999	Journal	1995–1998	RCT	Burkina Faso	Low	ZDV	80	Pill count	214	AN
Shaffer et al. [69]	1999	Full	1996–1997	RCT	Thailand	Middle	ZDV	100	Pill count	383	AN
Wiktor et al. [68]	1999	Full	1996–1998	RCT	Côte d'Ivoire	Middle	ZDV	100	Self-reported	134	AN
Laine et al. [31]	2000	Full	1993–1996	Obs.	USA	High	ZDV	80	Pharmacy-based	549	AN
Turner et al. [39]	2000	Full	1993–1996	Obs.	USA	High	ZDV	80	Pharmacy-based	292	PN
Wilson et al. [67]	2001	Full	1998	Obs.	USA	High	AZT	100	Pill count	247	AN
Chaovarindr et al. [27]	2002	Abstract	1999–2001	Obs.	Thailand	Middle	ZDV	100	Self-reported	350	AN
Ickovics et al. [64]	2002	Full	1997–1998	Obs.	USA	High	ZDV or cART	NR	MEMS	53	AN&PN
Durante et al. [58]	2003	Full	1998	Obs.	USA	High	cART	100	Self-reported	63	AN
Kiarie et al. [45]	2003	Full	1999–2001	Obs./RCT	Kenya	Low	cART	80	Self-reported	61/63	AN
Stringer et al. [44]	2003	Full	2000–2001	RCT	Zambia	Middle	sdNVP	NR	Cord blood	98/103	AN
Zorrilla et al. [55]	2003	Full	NR	Obs.	USA	High	cART	100	Self-reported	37	AN
Lallemant et al. [70]	2004	Full	2001–2003	Obs./RCT	Thailand	Middle	ZDV	90	Pill count	724/721	AN
Chung et al. [40]	2005	Full	2003	RCT	Kenya	Low	ZDV	100	Pill count	32	AN
Louis et al. [42]	2005	Full	1999–2004	Obs.	Kenya	High	cART	100	Self-reported	114	AN
Stringer et al. [50]	2005	Full	2003	Obs.	Zambia	Middle	sdNVP	100	Cord blood	1112	AN
Albrecht et al. [63]	2006	Full	2001–2003	Obs.	Zambia	Middle	sdNVP	100	Self-reported	711	AN
Shapiro et al. [60]	2006	Full	2002–2003	RCT	Botswana	Middle	ZDV	100	Self-reported	354/355	AN
Tedaldi et al. [46]	2006	Full	1997–1998	Obs.	USA	High	cART	100	Self-reported	29	PN
Bii et al. [66]	2007	Full	2005	Obs.	Kenya	Low	sdNVP	100	NR	146	AN
Cohn et al. [65]	2007	Full	2002–2005	Obs.	Kenya	High	cART	95	Self-reported	149	AN&PN
Kingston et al. [32]	2007	Full	2004–2005	Obs.	UK	High	cART	100	NR	32	AN
Vaz et al. [57]	2007	Full	2001–2002	Obs.	Brazil	Middle	cART	95	Pill count	72	AN&PN
Bardiguez et al. [34]	2008	Full	2002–2005	Obs.	USA	High	cART	100	Self-reported	445	AN&PN
Chi et al. [28]	2008	Full	2005–2007	RCT	Zambia	Middle	ZDV	100	Pharmacy refills	355	AN
Chung et al. [56]	2008	Full	2003–2006	RCT	Kenya	Low	cART	NR	NR	58	AN&PN
Giambrone et al. [29]	2008	Full	2003	Obs.	USA	Middle	cART	100	Self-reported	17	AN
Demas et al. [36]	2008	Full	1997–1998	Obs.	USA	High	ZDV	NR	red blood cell	78	AN
Imbaya et al. [30]	2008	Abstract	NR	Obs.	Kenya	Low	sdNVP/ ZDV	100	NR	326	AN
Peltzer et al. [54]	2008	Full	2006–2007	Obs.	South Africa	Middle	sdNVP	100	Self-reported	66	AN
Quava-Jones et al. [26]	2009	Abstract	2002–2008	Obs.	Trinidad & Tobago	High	cART	NR	Self-reported	461	AN & PN
Peltzer et al. [49]	2010	Full	2008–2009	Obs.	South Africa	Middle	sdNVP	100	Self-reported	815	AN
Barigye et al. [62]	2010	Full	2002–2007	Obs.	Uganda	Low	sdNVP	100	Self-reported	102	AN
Chasela et al. [59]	2010	Full	NR	RCT	Malawi	Low	cART	100	Self-reported	849	PN
Conkling et al. [47]	2010	Full	1986–1994	Obs.	Rwanda/ Zambia	Low/ Middle	sdNVP	100	Self-reported	185/319	AN
Kesho Bora [51]	2010	Full	2005–2006	Obs.	Burkina Faso & Kenya	Low	ZDV/sdNVP	100	Self-reported	116/319/127	AN
Kuonza et al. [61]	2010	Full	2008	Obs.	Zimbabwe	Low	sdNVP	100	Self-reported	212	AN
Megazzini et al. [43]	2010	Full	2005–2006	RCT	Zambia	Middle	sdNVP	100	Cord blood	234/264	AN
Mellins et al. [33]	2010	Full	2001–2005	Obs.	USA	High	cART	100	Self-reported	309	AN&PN
Shapiro et al. [37]	2010	Full	2006–2008	Obs./RCT	Botswana	Middle	cART	100	Self-reported	170/285/275	AN
Stringer et al. [74]	2010	Full	2007–2008	Obs.	Cameroon, Cote d'Ivoire, South Africa & Zambia	Low & Middle	sdNVP	100	Blood concentration	739/196/663/670	AN
Caswell et al. [73]	2011	Full	2004–2007	Obs.	UK	High	cART	100	NR	73	AN

Table 1 (continued)

Study	Publication year	Type of publication	Study year	Study design	Country	Income group	ARTs	Threshold	Adherence measure	Sample	Stage
Kesho Bora [71]	2011	Full	2005–2008	RCT	Burkina Faso, Kenya, South Africa	Low/Middle	cART	100	Self-reported	389/405/396	AN
Kirsten et al. [35]	2011	Full	2008–2009	Obs.	Tanzania	Low	cART	95	Pill count	86	AN&PN
Leisegang et al. [75]	2011	Abstract	NR	Obs.	South Africa	Middle	cART	NR	Pharmacy-based	293	NR
Manenti et al. [52]	2011	Full	2007	Obs.	Brazil	Middle	cART	NR	Self-reported	36	AN
Mepham et al. [41]	2011	Full	2008	Obs.	South Africa	Middle	cART	95	Pill count	94	AN
Mirkuze et al. [48]	2011	Full	2009	Obs.	Ethiopia	Low	cART	100	Self-reported	282	AN
Peltzer et al. [53]	2011	Full	2009	Obs.	South Africa	Middle	AZT	100	Self-reported	AN:139/PN:607	AN
Thomas et al. [72]	2011	Full	2003–2009	RCT	Kenya	Low	ZDV	100	Pill count	522	PN

AN, antepartum; cART, combined antiretroviral therapy; MEMS, Medication Events Monitoring System; NR, not reported; Obs, observation studies; PN, postpartum; RCT, randomized controlled trial; sdNVP, single-dose nevirapine; ZDV, zidovudine.

### Adherence to antiretroviral therapy by different subgroups

The results of subgroup analyses are shown in Fig. 3. The pooled proportion of patients who achieved adequate adherence levels was significantly higher during the antepartum (75.7%, 95% CI 71.5–79.7%) than during the postpartum period (53.0%, 95% CI 32.8–72.7%;  $P=0.005$ ). Similarly, the pooled adherence of patients with good adherence rate was significantly higher in low-income and middle-income countries (76.1%, 95% CI 72.2–79.7%) than in high-income countries (62.0%, 95% CI 50.1–73.3%;  $P=0.021$ ). However, the differential proportion of women who achieved adequate adherence levels between low-income and middle-income vs. high-income countries became nonsignificant when we excluded sdNVP studies (74.3 vs. 62.0%,  $P=0.062$ ) and when analyses were limited to more than 90% thresholds (74.8 vs. 69.7%,  $P=0.071$ ) and 100% thresholds (78.3 vs. 74.0%,  $P=0.103$ ).

Adherence proportions from RCTs evaluating PMTCT regimens were nonsignificantly higher than observational studies in proportion of patients with adequate ART adherence (79.6 vs. 70.4%,  $P=0.086$ ). Also, the pooled proportions were higher among women on ZDV (79.0%, 95% CI 70.2–86.6%) and women on sdNVP (78.6%, 95% CI 73.5–83.4%) than those on triple regimens cART (63.5%, 95% CI 55.8–70.8%;  $P=0.006$ ). Studies that used pill counts (73.0%, 95% CI 60.7–83.7%;  $P=0.017$ ) and self-reported questionnaires (74.2%, 95% CI 60.7–83.7%;  $P=0.015$ ) tended to report higher adherence proportions than those studies that used pharmacy refills or claims-based measures (44.7%, 95% CI 20.4–70.4%).

### Association between maternal antiretroviral therapy adherence and mother-to-child transmission of HIV

Fifteen studies reported 22 estimates of MTCT rates (all from low-income and middle-income countries). When reported, the MTCT rates ranged from 0.4 to 30.3% (median = 8.7%). There was negative but not statistically significant correlation between maternal ART adherence rates and MTCT rates (Pearson correlation  $r=-0.072$ ,  $P=0.751$ ). As shown in Fig. 4, the negative association between maternal ART adherence and MTCT rates tended to be stronger for women on ZDV or sdNVP ( $r=-0.439$ ,  $P=0.102$ ) than women on HAART ( $r=-0.175$ ,  $P=0.708$ ).

### Factors modifying adherence estimates as identified by meta-regression analyses

Factors associated with adherence estimates and proportion of explained variability in adherence estimates as identified by both unadjusted and adjusted logistic random-effect modeling are shown in Table 2. In the multivariable model, only ART type and adherence measure remained being statistically significantly associated with ART adherence. Adherence estimates from





Fig. 2. Pooled proportion of pregnant women to antiretroviral therapy. CI, confidence interval.



**Fig. 3. Pooled proportion of pregnant women to antiretroviral therapy, by different subgroups.** cART, combined antiretroviral therapy; sdNVP, single-dose nevirapine; ZDV, zidovudine.

cART studies were lower than those from sdNVP studies (OR = 0.48, 95% CI 0.28–0.80) and lower among studies that used pharmacy-based measures than other measures (OR = 0.25, 95% CI 0.09–0.70). The four factors included in the adjusted model jointly account for almost one-third (29%) of the variability in the adherence estimates.

**Factors associated with adherence rates as reported in individual studies**


Twenty-two studies (45%) reported factors associated with adherence. Appendices eTable 1 and eTable 2,

<http://links.lww.com/QAD/A254> provide study-specific data on factors associated with adherence in individual studies.

**Discussion**

To our knowledge, this is the first systematic review and meta-analysis to summarize the available data regarding ART adherence during and after pregnancy. The pooled proportion of pregnant women with adequate (>80%)





**Fig. 4. Association between maternal antiretroviral therapy adherence rates and mother-to-child transmission rates.** Area of circle is proportional to the sample size. ART, antiretroviral therapy; sdNVP, single-dose nevirapine; ZDV, zidovudine.

ART adherence was only about 72%. Importantly, a recent literature review of gender and ART adherence in high-income countries concluded that female gender was associated with lower adherence than men, although it did not address pregnancy issues [76]. This is potentially related to the association between family and other care-taking responsibilities and lower adherence rates [77,78]. Many HIV-infected women are first diagnosed during pregnancy and are still dealing with the implications of this diagnosis when they are prescribed ART drugs. Our study confirms that optimal adherence is a challenge during pregnancy and the postpartum period. The finding of better adherence during pregnancy than postpartum may be attributable to maternal concerns during the antepartum period regarding health of the fetus and prevention of MTCT. However, even during pregnancy, adherence was lower than is thought to be required for viral suppression and prevention of drug resistance [8,10–12].

‘Morning sickness’ is common in early pregnancy and may contribute to reduced adherence during this period [79]. Nausea and vomiting affect 70–85% of pregnant women in early pregnancy and may be exacerbated by other medications (e.g. ZDV), particularly those that may also have common gastrointestinal side-effects. Heartburn also occurs in later pregnancy and may affect medication-taking behaviors. After delivery, physical, economic, and emotional stresses, including the stresses and demands of caring for a new baby might make adherence more difficult. Postpartum depression (PPD) may also impact adherence. PPD is a subset of major depressive disorder that crosses cultures and affects approximately 13% of women [80]; a recent systematic review [81] found that the prevalence of PPD among women in developing countries was 31.3% (95% CI, 21.3–43.5%), higher than PPD prevalence among women from developed countries. Adherence in early pregnancy may also be affected by maternal concerns about safety of ART drugs for the fetus.

As documented in the studies evaluated in this review, pregnancy status can be associated with reduced ART adherence due to health factors associated with non-adherence such as advanced AIDS stage and health-related symptoms (nausea, fatigue, etc.) related to pregnancy, HIV disease, or toxicity of the ART regimen itself. In addition, there was a high prevalence of individual level barriers to ART adherence such as physical, economic, and emotional stresses, depression (especially postdelivery), alcohol or drug use, and drug regimen frequency or pill burden. Of note, key factors associated with high ART adherence reported in several studies were disclosure of HIV status as well as social support, in agreement with other studies in the general population [82,83].

Our study has several implications. Evaluation and management of mental health and illicit drug use during and following pregnancy should be a high priority for healthcare workers in charge of all HIV-infected pregnant women [84]. Social support and facilitation of HIV-serostatus disclosure, whenever feasible and safe, should

**Table 2. Factors associated with adherence estimates identified by unadjusted and adjusted meta-regression.**

Factor	Univariable (unadjusted)			Multivariable (adjusted)		
	OR (95% CI)	P	R <sup>2</sup>	OR (95% CI)	P	R <sup>2</sup>
Antepartum (vs. postpartum)	2.88 (1.38–6.01)	0.005	10.6	1.88 (0.93–3.80)	0.077	29.4%
Abstract (vs. journal article)	1.60 (0.52–4.92)	0.408	0.0	Ni		
RCTs (vs. observational) studies	1.65 (0.93–2.93)	0.086	3.5	Ni		
LMIC (vs. high-income)	2.07 (1.12–3.82)	0.021	8.4	1.05 (0.56–1.98)	0.871	
ZDV (vs. sdNVP)	1.68 (0.97–2.93)	0.066	4.2	Ni		
cART (vs. sdNVP)	0.44 (0.27–0.71)	0.001	15.0	0.48 (0.29–0.80)	0.006	
Pharmacy refills (vs. others)	0.25 (0.09–0.72)	0.011	10.1	0.25 (0.09–0.70)	0.009	

cART, triple regimens, combined antiretroviral therapy; CI, confidence interval; LMIC, low-income and middle-income countries; Ni, not included in the adjusted model; OR, odds ratio; RCTs, randomized controlled trials; sdNVP, single dose nevirapine; ZDV, zidovudine. R<sup>2</sup>, proportion of variability (statistical heterogeneity) in adherence estimates explained by study level factors.

be encouraged as it is effective in improving adherence to PMTCT [48,49,53]. The use of cART is recommended by WHO in pregnancy and after delivery when women meet indications for treatment. The recent changes in WHO recommendations to consider where feasible, the use of cART (instead of sdNVP) for prophylaxis in pregnant women reflect the increased effectiveness in PMTCT of longer and more complex regimens [2,85–87] for the mother coupled with extension of maternal or infant prophylaxis during the neonatal/breastfeeding period [88–90]. The WHO has also endorsed consideration of the approach of initiating life-long cART in all pregnant women regardless of CD4 cell count, which has been adopted as national policy in Malawi [91,92]. These new recommendations reflect the benefits of earlier initiation of ART for maternal health and infant survival, as well as to optimize PMTCT. However, they also magnify the challenges to good adherence. The findings of our study have implications for the WHO goal of elimination of MTCT by 2015 [7], as the ability to reduce transmission to the greatest extent possible depends not only on the availability and accessibility of the most effective regimens, but also on the ability of women to take these medications appropriately and to give full prophylactic regimens to their infants. There is a critical and urgent need to assist HIV providers to more reliably monitor adherence and develop evidence-based interventions to improve and/or maintain adherence in HIV-infected individuals [85], particularly pregnant and postpartum women as PMTCT programs move toward universal use of cART, potentially life-long, for all pregnant women. Without close monitoring and adherence support, suboptimal adherence levels would likely to increase the likelihood of multiclass drug resistance acquisition for both the mother and infant and compromise the safety and scale-up of PMTCT with cART [93,94].

In many programs, nonmedical personnel such as lay or peer counselors play an important role [86]. A number of programs have documented the feasibility and acceptance of this method of supplementing clinic-based staff [87]. However, there are limited data on the impact of these support staff on the overall effectiveness of PMTCT programs and ART adherence, particularly in pregnant and postpartum women. Although some observational studies seem to suggest that peer support can improve ART prophylaxis adherence in pregnant women [88,89], more research is needed to better evaluate the effectiveness and cost-effectiveness of such interventions. Indeed, a trial with peer mentors to improve maternal ART adherence antenatally and at the time of birth is underway in South Africa [90]. Furthermore, using a mathematical model, McCabe *et al.* [91] found that programs aimed at optimizing ART adherence using directly observed therapy would be cost-effective to decrease MTCT. Another trial, also underway in South Africa, is investigating the role of male involvement in PMTCT

ART adherence [92]. The use of regimens with easier dosing requirements, reduced pill burden, and better tolerability profiles may also help optimize ART adherence in pregnant women [85,93].

Strengths of our study include its novelty, timeliness, and the comprehensive search of several databases and sources to identify studies globally. We found no evidence of publication bias [94] and used random-effects models to produce a robust pooled adherence estimate. In addition, we also conducted meta-regression analyses to investigate whether any particular study-level factor explained the results and could account for the observed variations between studies.

There are also some limitations of our study. Adherence estimates from different study designs and settings were pooled in this meta-analysis, and as expected high heterogeneity between studies was found in the meta-analysis. Considerable amount of this heterogeneity could be explained by factors such as population, regimens, or study methodology. However, even in the presence of high heterogeneity, meta-analysis has been suggested as preferred option to qualitative or narrative interpretation of the results, because narrative synthesis can lead to misleading or wrong conclusions [95]. Quantitative accuracy is an important feature of meta-analysis, one of the reasons for avoiding narrative interpretation without synthesis [95]. Heterogeneity appeared to be the norm rather than exception in published ART adherence meta-analyses [96–99]. Another limitation is the possibility of information bias that can be introduced by the methods used for measuring adherence. Indeed, most of the studies included in this meta-analysis used self-reported or pill count adherence which may overestimate adherence levels, and only a few studies used objective methods such as MEMS caps and blood drug concentrations. However, there is a conservative bias with self-report and pill counts, leading to possible overestimation of adherence and potentially actual levels of ART adherence being even lower than what we are reporting. To date, however, there is no established gold standard to measure ART adherence as each measurement method has unique strengths and weaknesses [85]. Finally, the meta-regression analysis has several limitations. Meta-regression represents an observational association and suffers from ecological fallacy [100]. In addition, meta-regression has low statistical power to detect an association and is easily influenced by an outlier [101].

In conclusion, our meta-analysis showed that ART adherence during pregnancy is significantly below that recommended for adequate virologic suppression. Optimal adherence remains a challenge in pregnancy, in both high-income and low-income countries, and particularly during the postpartum period. It is crucial to monitor ART adherence, investigate specific barriers for nonadherence, and develop interventions to assist

antepartum and postpartum women in adhering to ART and ensure the long-term efficacy of such an approach for both maternal health and PMTCT.

## Acknowledgements

The authors thank James Kiarie, MD, University of Nairobi, Kenya; David Dowdy, MD, PhD, Johns Hopkins University, Baltimore, MD, USA; Charles Wiysonge, MD, PhD, University of Cape Town, South Africa, for critical reading of this article; Laura Bernard, MPH and Kathryn Muessig, PhD, University of North Carolina, Chapel Hill, NC, USA, for research support and editorial assistance.

J.B.N. and O.A.U. had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

J.B.N., O.A.U., and E.J.M. contributed to study concept and design.

J.B.N., O.A.U., and Y-S.H. contributed to acquisition of data.

All the authors contributed to analysis and interpretation of data.

J.B.N., O.A.U., L.M.M., J.A., K.P., S.W., and J.S.A.S. contributed to drafting or writing of the article.

All authors contributed to the critical revision of the article for important intellectual content.

O.A.U., J.B.N., and E.J.M. contributed to statistical analysis.

J.B.N., E.J.M., O.A.U., and Y-S.H. contributed to administrative, technical, or material support.

J.B.N. and E.J.M. contributed to study supervision.

The authors acknowledge research support from The US National Institutes for Allergy and Infectious Disease-National Institutes of Health (NIAID-NIH), Division of AIDS (DAIDS): R01 AI005535901 and K23 AI 068582-01 (J.B.N.); The US NIH-Fogarty International Center (FIC)/Health Resources and Services Administration (HRSA)/US President Emergency Plan for AIDS Relief (PEPFAR) Grant Award, T84HA21652-01-00 for Medical Education Partnership Initiative (MEPI) (J.B.N.); The European Developing Countries Clinical Trial Partnership (EDCTP) Senior Fellowship Award: TA-08-40200- 021 (J.B.N.); The Wellcome Trust Southern Africa Consortium for Research Excellence (SACORE): WT087537MA (J.B.N.); the NIMH-NIH R34 MH083592-01A1 (E.J.M.); The Framework in

Global Health Award and the Global Field Experience Fund from Johns Hopkins University Center for Global Health (S.W.).

The agencies had no role in the conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the article. The conclusions and opinions expressed in this article are those of the author and do not necessarily reflect those of the NIH or US Department of Health and Human Services or PEPFAR or HRSA or the Wellcome Trust.

## Conflicts of interest

There are no conflicts of interest.

*The present study was accepted for presentation at the 19th Conference on Retroviruses and Opportunistic Infections, Washington State Convention Center, Seattle, WA, USA, 5-8 March 2012. Website: <http://www.retroconference.org/>.*

## References

1. World Health Organization. *Towards universal access: scaling up priority HIV/AIDS interventions in the health sector, progress report 2010*. Geneva, Switzerland: World Health Organization; 2010.
2. Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. **Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006**. *AIDS* 2008; **22**:973-981.
3. De Cock KM, Fowler MG, Mercier E, de Vincenzi I, Saba J, Hoff E, et al. **Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice**. *JAMA* 2000; **283**:1175-1182.
4. Wiktor SZ, Ekpini E, Nduati RW. **Prevention of mother-to-child transmission of HIV-1 in Africa**. *AIDS* 1997; **11 (Suppl B)**: S79-S87.
5. World Health Organization. *Antiretroviral drugs for treating pregnant women and preventing HIV infections in infants: recommendations for a public health approach: 2010 version*. Geneva, Switzerland: World Health Organization; 2010.
6. World Health Organization. *Global HIV/AIDS response: epidemic update and health sector progress towards universal access*. Progress report 2011. Geneva: Switzerland: World Health Organization; 2011.
7. World Health Organization. *Countdown to zero: global plan for the elimination of new HIV infections among children by 2015 and keeping their mothers alive*. Geneva, Switzerland: World Health Organization; 2011.
8. Nachega JB, Marconi VC, van Zyl GU, Gardner EM, Preiser W, Hong SY, et al. **HIV treatment adherence, drug resistance, virologic failure: evolving concepts**. *Infect Disord Drug Targets* 2011; **11**:167-174.
9. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squires C, et al. **Adherence to protease inhibitor therapy and outcomes in patients with HIV infection**. *Ann Intern Med* 2000; **133**:21-30.
10. Kobin AB, Sheth NU. **Levels of adherence required for virologic suppression among newer antiretroviral medications**. *Ann Pharmacother* 2011; **45**:372-379.
11. Martin M, Del Cacho E, Codina C, Tuset M, De Lazzari E, Mallolas J, et al. **Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 RNA viral load: a prospective cohort study**. *AIDS Res Hum Retroviruses* 2008; **24**:1263-1268.
12. Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G. **Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes**. *Ann Intern Med* 2007; **146**:564-573.

13. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, *et al.* **Prevention of HIV-1 infection with early antiretroviral therapy.** *N Engl J Med* 2011; **365**:493–505.
14. Kaiser R, Bunnell R, Hightower A, Kim AA, Cherutich P, Mwangi M, *et al.* **Factors associated with HIV infection in married or cohabitating couples in Kenya: results from a nationally representative study.** *PLoS One* 2011; **6**:e17842.
15. Osinde MO, Kaye DK, Kakaire O. **Sexual behaviour and HIV sero-discordance among HIV patients receiving HAART in rural Uganda.** *J Obstet Gynaecol* 2011; **31**:436–440.
16. Stuart A, Ord JK. *Kendall's advanced theory of statistics.* London, England: Arnold Publishers; 1994.
17. DerSimonian R, Laird N. **Meta-analysis in clinical trials.** *Control Clin Trials* 1986; **7**:177–188.
18. Normand SL. **Meta-analysis: formulating, evaluating, combining, and reporting.** *Stat Med* 1999; **18**:321–359.
19. Higgins JP, Thompson SG. **Quantifying heterogeneity in a meta-analysis.** *Stat Med* 2002; **21**:1539–1558.
20. Higgins JP, Thompson SG, Deeks JJ, Altman DG. **Measuring inconsistency in meta-analyses.** *BMJ* 2003; **327**:557–560.
21. Begg CB, Mazumdar M. **Operating characteristics of a rank correlation test for publication bias.** *Biometrics* 1994; **50**:1088–1101.
22. Egger M, Davey SG, Schneider M, Minder C. **Bias in meta-analysis detected by a simple, graphical test.** *BMJ* 1997; **315**:629–634.
23. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, *et al.* **The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.** *BMJ* 2009; **339**:b2700.
24. Moher D, Liberati A, Tetzlaff J, Altman DG. **Preferred Reporting Items For Systematic Reviews and Meta-Analyses: the PRISMA statement.** *BMJ* 2009; **339**:b2535.
25. Dabis F, Msellati P, Meda N, Welffens-Ekra C, You B, Manigart O, *et al.* **6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial.** **DITRAME Study Group.** *Diminution de la Transmission Mere-Enfant.* *Lancet* 1999; **353**:786–792.
26. Quava-Jones A. **Adherence to antiretrovirals during and after pregnancy in women attending an HIV treatment clinic in Trinidad** (abstract no. CDC012). In: *5th IAS Conference on HIV Pathogenesis and Treatment.* Cape Town, South Africa; 2009.
27. Chaovarindr U, Chalermchokcharoenkit A, Asavapiriyant S, Sirimai K, Culnane M, Teeraratkul A, *et al.* **Acceptance of and adherence to zidovudine and infant formula for preventing mother-child HIV transmission, Bangkok, Thailand.** *Symposium Session: The XIV International AIDS Conference, Mexico City, 3–8 August, 2008* [Abstract no. ThOrD1430] <http://www.iasociety.org/Default.aspx?pageId=11&abstractId=4998> [Accessed 9 July 2011].
28. Chi BH, Chintu N, Cantrell RA, Kankasa C, Kruse G, Mbewe F, *et al.* **Addition of single-dose tenofovir and emtricitabine to intrapartum nevirapine to reduce perinatal HIV transmission.** *J Acquir Immune Defic Syndr* 2008; **48**:220–223.
29. Ciambrone D, Loewenthal HG, Bazerman LB, Zorilla C, Urbina B, Mitty JA. **Adherence among women with HIV infection in Puerto Rico: the potential use of modified directly observed therapy (MDOT) among pregnant and postpartum women.** *Women Health* 2006; **44**:61–77.
30. Imbaya CL, Odhiambo-Otieno GW, Okello-Agina BM. **Adherence levels to antenatal regimens of NVP and AZT among HIV+ women receiving PMTCT treatment at Pumwani Maternity Hospital in Nairobi, Kenya.** *AIDS 2008 – The XVII International AIDS Conference, Mexico City, 3–8 August 2008* [Abstract MOPE0519]. <http://www.iasociety.org/Abstracts/A200715665.aspx> [Accessed 9 July 2011].
31. Laine C, Newschaffer CJ, Zhang D, Cosler L, Hauck WW, Turner BJ. **Adherence to antiretroviral therapy by pregnant women infected with human immunodeficiency virus: a pharmacy claims-based analysis.** *Obstet Gynecol* 2000; **95**:167–173.
32. Kingston MA, Letham CJ, McQuillan O. **Adherence to antiretroviral therapy in pregnancy.** *Int J STD AIDS* 2007; **18**:787–789.
33. Mellins CA, Chu C, Malee K, Allison S, Smith R, Harris L, *et al.* **Adherence to antiretroviral treatment among pregnant and postpartum HIV-infected women.** *AIDS Care* 2008; **20**:958–968.
34. Bardeguet AD, Lindsey JC, Shannon M, Tuomala RE, Cohn SE, Smith E, *et al.* **Adherence to antiretrovirals among US women during and after pregnancy.** *J Acquir Immune Defic Syndr* 2008; **48**:408–417.
35. Kirsten I, Sewangi J, Kunz A, Dugange F, Ziske J, Jordan-Harder B, *et al.* **Adherence to combination prophylaxis for prevention of mother-to-child-transmission of HIV in Tanzania.** *PLoS One* 2011; **6**:e2120.
36. Demas PA, Thea DM, Weedon J, McWayne J, Bamji M, Lambert G, *et al.* **Adherence to zidovudine for the prevention of perinatal transmission in HIV-infected pregnant women: the impact of social network factors, side effects, and perceived treatment efficacy.** *Women Health* 2005; **42**:99–115.
37. Shapiro RL, Hughes MD, Ogwu A, Kitch D, Lockman S, Moffat C, *et al.* **Antiretroviral regimens in pregnancy and breast-feeding in Botswana.** *N Engl J Med* 2010; **362**:2282–2294.
38. Turner BJ, Newschaffer CJ, Hauck WW, Zhang D, Cosler L. **Antiretroviral use and adherence in a cohort of 696 HIV+ pregnant women** (abstract no. 32329). *Int Conf AIDS.* Geneva, Switzerland; 1998. p. 536.
39. Turner BJ, Newschaffer CJ, Zhang DZ, Cosler L, Hauck WW. **Antiretroviral use and pharmacy-based measurement of adherence in postpartum HIV-infected women.** *Med Care* 2000; **38**:911–925.
40. Chung MH, Kiarie JN, Richardson BA, Lehman DA, Overbaugh J, John-Stewart GC. **Breast milk HIV-1 suppression and decreased transmission: a randomized trial comparing HIVNET 012 nevirapine versus short-course zidovudine.** *AIDS* 2005; **19**:1415–1422.
41. Mephum S, Zondi Z, Mbuyazi A, Mkhwanazi N, Newell ML. **Challenges in PMTCT antiretroviral adherence in northern KwaZulu-Natal, South Africa.** *AIDS Care* 2011; **23**:741–747.
42. Louis JM, Buhari MA, Blackwell SC, Refuerzo J, Allen D, Gonik B, *et al.* **Characteristics associated with suboptimal viral suppression at delivery in human immunodeficiency virus-1-infected pregnant women.** *Am J Obstet Gynecol* 2005; **193**:1266–1269.
43. Megazzini KM, Sinkala M, Vermund SH, Redden DT, Krebs DW, Acosta EP, *et al.* **A cluster-randomized trial of enhanced labor ward-based PMTCT services to increase nevirapine coverage in Lusaka, Zambia.** *AIDS* 2010; **24**:447–455.
44. Stringer JS, Sinkala M, Stout JP, Goldenberg RL, Acosta EP, Chapman V, *et al.* **Comparison of two strategies for administering nevirapine to prevent perinatal HIV transmission in high-prevalence, resource-poor settings.** *J Acquir Immune Defic Syndr* 2003; **32**:506–513.
45. Kiarie JN, Kreiss JK, Richardson BA, John-Stewart GC. **Compliance with antiretroviral regimens to prevent perinatal HIV-1 transmission in Kenya.** *AIDS* 2003; **17**:65–71.
46. Tedaldi E, Willard S, Gilmore J, Holdsworth C, Dix-Lassiter S, Axelrod P. **Continuation of postpartum antiretroviral therapy in a cohort of women infected with human immunodeficiency virus.** *J Assoc Nurses AIDS Care* 2002; **13**:60–65.
47. Conkling M, Shutes EL, Karita E, Chomba E, Tichacek A, Sinkala M, *et al.* **Couples' voluntary counselling and testing and nevirapine use in antenatal clinics in two African capitals: a prospective cohort study.** *J Int AIDS Soc* 2010; **13**:10.
48. Mirkuzie AH, Hinderaker SG, Sisay MM, Moland KM, Morkve O. **Current status of medication adherence and infant follow up in the prevention of mother to child HIV transmission programme in Addis Ababa: a cohort study.** *J Int AIDS Soc* 2011; **14**:50.
49. Peltzer K, Mlambo M, Phaswana-Mafuya N, Ladzani R. **Determinants of adherence to a single-dose nevirapine regimen for the prevention of mother-to-child HIV transmission in Gert Sibande district in South Africa.** *Acta Paediatr* 2010; **99**:699–704.
50. Stringer JS, Sinkala M, Maclean CC, Levy J, Kankasa C, Degroot A, *et al.* **Effectiveness of a city-wide program to prevent mother-to-child HIV transmission in Lusaka, Zambia.** *AIDS* 2005; **19**:1309–1315.

51. Kesho Bora Study Group. **Eighteen-month follow-up of HIV-1-infected mothers and their children enrolled in the Kesho Bora study observational cohorts.** *J Acquir Immune Defic Syndr* 2010; **54**:533–541.
52. Manenti SA, Galato JJ, Silveira ES, Oenning RT, Simoes PW, Moreira J, et al. **Epidemiologic and clinical characteristics of pregnant women living with HIV/AIDS in a region of southern Brazil where the subtype C of HIV-1 infection predominates.** *Braz J Infect Dis* 2011; **15**:349–355.
53. Peltzer K, Sikwane E, Majaja M. **Factors associated with short-course antiretroviral prophylaxis (dual therapy) adherence for PMTCT in Nkangala district, South Africa.** *Acta Paediatr* 2011; **100**:1253–1257.
54. Peltzer K, Mosala T, Dana P, Fomundam H. **Follow-up survey of women who have undergone a prevention of mother-to-child transmission program in a resource-poor setting in South Africa.** *J Assoc Nurses AIDS Care* 2008; **19**:450–460.
55. Zorrilla CD, Santiago LE, Knudson D, Liberatore K, Estronza G, Colon O, et al. **Greater adherence to highly active antiretroviral therapy (HAART) between pregnant versus nonpregnant women living with HIV.** *Cell Mol Biol* 2003; **49**:1187–1192.
56. Chung MH, Kiarie JN, Richardson BA, Lehman DA, Overbaugh J, Kinuthia J, et al. **Highly active antiretroviral therapy versus zidovudine/nevirapine effects on early breast milk HIV type-1 RNA: a phase II randomized clinical trial.** *Antivir Ther* 2008; **13**:799–807.
57. Vaz MJ, Barros SM, Palacios R, Senise JF, Lunardi L, Amed AM, et al. **HIV-infected pregnant women have greater adherence with antiretroviral drugs than nonpregnant women.** *Int J STD AIDS* 2007; **18**:28–32.
58. Durante AJ, Bova CA, Fennie KP, Danvers KA, Holness DR, Burgess JD, et al. **Home-based study of anti-HIV drug regimen adherence among HIV-infected women: feasibility and preliminary results.** *AIDS Care* 2003; **15**:103–115.
59. Chasela CS, Hudgens MG, Jamieson DJ, Kayira D, Hosseini-pour MC, Kourtis AP, et al. **Maternal or infant antiretroviral drugs to reduce HIV-1 transmission.** *N Engl J Med* 2010; **362**:2271–2281.
60. Shapiro RL, Thior I, Gilbert PB, Lockman S, Wester C, Smeaton LM, et al. **Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana.** *AIDS* 2006; **20**:1281–1288.
61. Kuonza LR, Tshuma CD, Shambira GN, Tshimanga M. **Non-adherence to the single dose nevirapine regimen for the prevention of mother-to-child transmission of HIV in Bindura town, Zimbabwe: a cross-sectional analytic study.** *BMC Public Health* 2010; **10**:218.
62. Barigye H, Levin J, Maher D, Tindiwegi G, Atuhumuza E, Nakibinge S, et al. **Operational evaluation of a service for prevention of mother-to-child transmission of HIV in rural Uganda: barriers to uptake of single-dose nevirapine and the role of birth reporting.** *Trop Med Int Health* 2010; **15**:1163–1171.
63. Albrecht S, Semrau K, Kasonde P, Sinkala M, Kankasa C, Wwalika C, et al. **Predictors of nonadherence to single-dose nevirapine therapy for the prevention of mother-to-child HIV transmission.** *J Acquir Immune Defic Syndr* 2006; **41**:114–118.
64. Ickovics JR, Wilson TE, Royce RA, Minkoff HL, Fernandez MI, Fox-Tierney R, et al. **Prenatal and postpartum zidovudine adherence among pregnant women with HIV: results of a MEMS substudy from the Perinatal Guidelines Evaluation Project.** *J Acquir Immune Defic Syndr* 2002; **30**:311–315.
65. Cohn SE, Umbleja T, Mrus J, Bardeguez AD, Andersen JW, Chesney MA. **Prior illicit drug use and missed prenatal vitamins predict nonadherence to antiretroviral therapy in pregnancy: adherence analysis A5084.** *AIDS Patient Care STDS* 2008; **22**:29–40.
66. Bii SC, Otieno-Nyunya B, Siika A, Rotich JK. **Self-reported adherence to single dose nevirapine in the prevention of mother to child transmission of HIV at Kitale District Hospital.** *East Afr Med J* 2007; **84**:571–576.
67. Wilson TE, Ickovics JR, Fernandez MI, Koenig LJ, Walter E. **Self-reported zidovudine adherence among pregnant women with human immunodeficiency virus infection in four US states.** *Am J Obstet Gynecol* 2001; **184**:1235–1240.
68. Wiktor SZ, Ekpini E, Karon JM, Nkengasong J, Maurice C, Severin ST, et al. **Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire: a randomised trial.** *Lancet* 1999; **353**:781–785.
69. Shaffer N, Chuachoowong R, Mock PA, Bhadrakom C, Siriwasin W, Young NL, et al. **Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial.** Bangkok Collaborative Perinatal HIV Transmission Study Group. *Lancet* 1999; **353**:773–780.
70. Lallemand M, Jourdain G, Le Coeur S, Mary JY, Ngo-Giang-Huong N, Koetsawang S, et al. **Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.** *N Engl J Med* 2004; **351**:217–228.
71. de Vincenzi I. **Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial.** *Lancet Infect Dis* 2011; **11**:171–180.
72. Thomas TK, Masaba R, Borkowf CB, Ndivo R, Zeh C, Misore A, et al. **Triple-antiretroviral prophylaxis to prevent mother-to-child HIV transmission through breastfeeding: the Kisumu Breastfeeding Study, Kenya – a clinical trial.** *PLoS Med* 2011; **8**:e1001015.
73. Caswell RJ, Phillips D, Chaponda M, Khoo SH, Taylor GP, Ghanem M, et al. **Utility of therapeutic drug monitoring in the management of HIV-infected pregnant women in receipt of lopinavir.** *Int J STD AIDS* 2011; **22**:11–14.
74. Stringer EM, Ekouevi DK, Coetzee D, Tih PM, Creek TL, Stinson K, et al. **Coverage of nevirapine-based services to prevent mother-to-child HIV transmission in 4 African countries.** *JAMA* 2010; **304**:293–302.
75. Leisegang R, Nachega JB, Hislop M, Maartens G. **The impact of pregnancy on adherence to and default from ART.** In: *18th Conference on Retroviruses and Opportunistic Infections*; 2011.
76. Puskas CM, Forrest JI, Parashar S, Salters KA, Cescon AM, Kaida A, et al. **Women and vulnerability to HAART non-adherence: a literature review of treatment adherence by gender from 2000 to 2011.** *Curr HIV/AIDS Rep* 2011; **8**:277–287.
77. Merenstein D, Schneider MF, Cox C, Schwartz R, Weber K, Robison E, et al. **Association of child care burden and household composition with adherence to highly active antiretroviral therapy in the Women's Interagency HIV Study.** *AIDS Patient Care STDS* 2009; **23**:289–296.
78. Merenstein DJ, Schneider MF, Cox C, Schwartz R, Weber K, Robison E, et al. **Association between living with children and adherence to highly active antiretroviral therapy in the Women's Interagency HIV Study.** *Pediatrics* 2008; **121**:e787–e793.
79. ACOG (American College of Obstetrics and Gynecology). **Practice Bulletin: nausea and vomiting of pregnancy.** *Obstet Gynecol* 2004; **103**:803–814.
80. Breese McCoy SJ. **Postpartum depression: an essential overview for the practitioner.** *South Med J* 2011; **104**:128–132.
81. Villegas L, McKay K, Dennis CL, Ross LE. **Postpartum depression among rural women from developed and developing countries: a systematic review.** *J Rural Health* 2011; **27**:278–288.
82. Mills EJ, Nachega JB, Bangsberg DR, Singh S, Rachlis B, Wu P, et al. **Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators.** *PLoS Med* 2006; **3**:e438.
83. Ware NC, Idoko J, Kaaya S, Biraro IA, Wyatt MA, Agbaji O, et al. **Explaining adherence success in sub-Saharan Africa: an ethnographic study.** *PLoS Med* 2009; **6**:e11.
84. Stoff DM, Mitnick L, Kalichman S. **Research issues in the multiple diagnoses of HIV/AIDS, mental illness and substance abuse.** *AIDS Care* 2004; **16** (Suppl 1):S1–S5.
85. Thompson MA, Mugavero MJ, Amico KR, Cargill VA, Chang LW, Gross R, et al. **Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel.** *Ann Intern Med* 2012; **156**:817–833.
86. Zachariah R, Ford N, Phillips M, Lynch S, Massaquoi M, Janssens V, et al. **Task shifting in HIV/AIDS: opportunities, challenges and proposed actions for sub-Saharan Africa.** *Trans R Soc Trop Med Hyg* 2009; **103**:549–558.

87. Shetty AK, Marangwanda C, Stranix-Chibanda L, Chandisarewa W, Chirapa E, Mahomva A, *et al*. **The feasibility of preventing mother-to-child transmission of HIV using peer counselors in Zimbabwe.** *AIDS Res Ther* 2008; **5**:17.
88. Baek C, Mathambo V, Mkhize S, Friedman I, Apicella L, Rutenberg N. *Key findings from an evaluation of the mothers2mothers program in KwaZulu-Natal, South Africa.* New York: Horizons Program & Health Systems Trust; 2007.
89. Zuyderduin JR, Ehlers VJ, Van der Wal D. **The impact of a buddy system on the self-care behaviours of women living with HIV/AIDS in Botswana.** *Health SA Gesondheid* 2008; **13**:4–15.
90. Rotheram-Borus MJ, Richter L, Van Rooyen H, van Heerden A, Tomlinson M, Stein A, *et al*. **Project Masihambisane Protocol: a cluster randomised controlled trial with peer mentors to improve outcomes for pregnant mothers living with HIV.** *Trials* 2011; **12**:2.
91. McCabe CJ, Goldie SJ, Fisman DN. **The cost-effectiveness of directly observed highly-active antiretroviral therapy in the third trimester in HIV-infected pregnant women.** *PLoS One* 2010; **5**:e10154.
92. Peltzer K, Jones D, Weiss SM, Shikwane E. **Promoting male involvement to improve PMTCT uptake and reduce antenatal HIV infection: a cluster randomized controlled trial protocol.** *BMC Public Health* 2011; **11**:778.
93. Fogel J, Li Q, Taha TE, Hoover DR, Kumwenda NI, Mofenson LM, *et al*. **Initiation of antiretroviral treatment in women after delivery can induce multiclass drug resistance in breast-feeding HIV-infected infants.** *Clin Infect Dis* 2011; **52**:1069–1076.
94. Zeh C, Weidle PJ, Nafisa L, Lwamba HM, Okonji J, Anyango E, *et al*. **HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis.** *PLoS Med* 2011; **8**:e1000430.
95. Nachega JB, Mugavero MJ, Zeier M, Vitoria M, Gallant JE. **Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs.** *Patient Prefer Adherence* 2011; **5**:357–367.
96. Lau J, Ioannidis JP, Terrin N, Schmid CH, Olkin I. **The case of the misleading funnel plot.** *BMJ* 2006; **333**:597–600.
97. Ioannidis JP, Patsopoulos NA, Rothstein HR. **Reasons or excuses for avoiding meta-analysis in forest plots.** *BMJ* 2008; **336**:1413–1415.
98. Malta M, Magnanini MM, Strathdee SA, Bastos FI. **Adherence to antiretroviral therapy among HIV-infected drug users: a meta-analysis.** *AIDS Behav* 2010; **14**:731–747.
99. Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, Singh S, *et al*. **Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis.** *JAMA* 2006; **296**:679–690.
100. Thompson SG, Higgins JP. **How should meta-regression analyses be undertaken and interpreted?** *Stat Med* 2002; **21**:1559–1573.
101. Lambert PC, Sutton AJ, Abrams KR, Jones DR. **A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis.** *J Clin Epidemiol* 2002; **55**:86–94.